Yervoy and Cholangitis sclerosing - a phase IV clinical study of FDA data

Summary:

Cholangitis sclerosing is reported as a side effect among people who take Yervoy (ipilimumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Opdivo, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Cholangitis sclerosing when taking Yervoy. It is created by eHealthMe based on reports of 26,647 people who have side effects when taking Yervoy from the FDA, and is updated regularly.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

What is Cholangitis sclerosing?

Cholangitis sclerosing (infection and obstruction of bile duct) is found to be associated with 186 drugs and 283 conditions by eHealthMe. Check the latest studies of Cholangitis sclerosing.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

26,647 people reported to have side effects when taking Yervoy.
Among them, 56 people (0.21%) have Cholangitis sclerosing.

Could Yervoy cause Cholangitis sclerosing?

Among these 56 people:

How long have people been on Yervoy when they have Cholangitis sclerosing? *

What is the gender of people who have Cholangitis sclerosing when taking Yervoy? *

female: 20.45 %
male: 79.55 %

What is the age of people who have Cholangitis sclerosing when taking Yervoy? *

What are other drugs people take besides Yervoy? *

What are other side effects people have besides Cholangitis sclerosing? *

Pneumonia: 7 people, 12.50%
Fever: 6 people, 10.71%
Vanishing Bile Duct Syndrome (loose collection of diseases which leads to the injury to hepatic bile ducts and eventual ductopenia): 5 people, 8.93%
Erythema Multiforme (a type of hypersensitivity reaction): 5 people, 8.93%
Lung Cancer - Non-Small Cell (lung cancer): 5 people, 8.93%
Hepatic Function Abnormal: 5 people, 8.93%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 4 people, 7.14%
Biloma (extrabiliary collection of bile): 3 people, 5.36%
Hepatic Haemorrhage (bleeding inside liver): 3 people, 5.36%
Blood Bilirubin Increased: 3 people, 5.36%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 13 people, 23.21%
Lung Cancer - Non-Small Cell (lung cancer): 12 people, 21.43%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 11 people, 19.64%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 8 people, 14.29%
Renal Cell Carcinoma (a kidney cancer): 5 people, 8.93%
Constipation: 3 people, 5.36%
Cachexia (loss of weight): 3 people, 5.36%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 2 people, 3.57%
Oesophageal Carcinoma (cancer tumour of oesophagus): 2 people, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Yervoy and have Cholangitis sclerosing?

- Check whether Cholangitis sclerosing is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yervoy:

Yervoy (26,662 reports)

Browse all side effects of Yervoy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cholangitis sclerosing:

Cholangitis sclerosing (186 drugs)

Browse all the conditions that are associated with Cholangitis sclerosing:

Cholangitis sclerosing (283 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ipilimumab (the active ingredients of Yervoy) and Yervoy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.